ZA200606310B - Pharmaceutical compositions comprising midazolam in a high concentration - Google Patents
Pharmaceutical compositions comprising midazolam in a high concentrationInfo
- Publication number
- ZA200606310B ZA200606310B ZA200606310A ZA200606310A ZA200606310B ZA 200606310 B ZA200606310 B ZA 200606310B ZA 200606310 A ZA200606310 A ZA 200606310A ZA 200606310 A ZA200606310 A ZA 200606310A ZA 200606310 B ZA200606310 B ZA 200606310B
- Authority
- ZA
- South Africa
- Prior art keywords
- midazolam
- pharmaceutical compositions
- high concentration
- compositions
- benzodiazapine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0400804.1A GB0400804D0 (en) | 2004-01-14 | 2004-01-14 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200606310B true ZA200606310B (en) | 2007-12-27 |
Family
ID=31726180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200606310A ZA200606310B (en) | 2004-01-14 | 2006-07-31 | Pharmaceutical compositions comprising midazolam in a high concentration |
Country Status (23)
Country | Link |
---|---|
US (2) | US7700588B2 (xx) |
EP (1) | EP1703896B1 (xx) |
JP (1) | JP5085138B2 (xx) |
KR (1) | KR20060130175A (xx) |
CN (1) | CN1929816B (xx) |
AT (1) | ATE417600T1 (xx) |
AU (1) | AU2005205072B2 (xx) |
BR (1) | BRPI0506868A (xx) |
CA (1) | CA2553890C (xx) |
DE (1) | DE602005011753D1 (xx) |
DK (1) | DK1703896T3 (xx) |
EA (1) | EA014096B1 (xx) |
ES (1) | ES2319667T3 (xx) |
FI (2) | FIC20230023I1 (xx) |
GB (1) | GB0400804D0 (xx) |
IL (1) | IL176774A0 (xx) |
MX (1) | MXPA06008086A (xx) |
NO (3) | NO336916B1 (xx) |
NZ (1) | NZ548454A (xx) |
PL (1) | PL1703896T3 (xx) |
PT (1) | PT1703896E (xx) |
WO (1) | WO2005067893A2 (xx) |
ZA (1) | ZA200606310B (xx) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
PL2623113T3 (pl) | 2005-11-09 | 2018-05-30 | Onyx Therapeutics, Inc. | Związek do hamowania enzymu |
EP2484688B1 (en) | 2006-06-19 | 2016-06-08 | Onyx Therapeutics, Inc. | Peptide epoxyketones for proteasome inhibition |
ES2611995T3 (es) * | 2007-01-19 | 2017-05-11 | Hananja Ehf | Métodos y composiciones para el suministro de un agente terapéutico |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
JP5539875B2 (ja) | 2007-08-31 | 2014-07-02 | アルキメデス・デベロップメント・リミテッド | 非水性医薬組成物 |
US8507468B2 (en) * | 2007-10-02 | 2013-08-13 | Robert Orr | Intranasal anti-convulsive compositions and methods |
US8367617B2 (en) | 2007-10-04 | 2013-02-05 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
US20090258865A1 (en) | 2008-03-28 | 2009-10-15 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
EP3090737A1 (en) | 2008-10-21 | 2016-11-09 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
JP6042724B2 (ja) | 2010-03-01 | 2016-12-14 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | イムノプロテアソーム阻害のための化合物 |
EP2555621A4 (en) | 2010-04-07 | 2014-07-02 | Onyx Therapeutics Inc | CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR |
GB2481407B (en) * | 2010-06-22 | 2012-05-23 | Special Products Ltd | A rapid onset liquid midazolam composition for buccal administration |
CN102309438B (zh) * | 2010-07-02 | 2013-04-17 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种咪达唑仑药物组合物及其用途 |
CN102335430B (zh) * | 2010-07-14 | 2013-07-31 | 中国人民解放军军事医学科学院毒物药物研究所 | 包含咪达唑仑与神经保护剂的复方药物组合物 |
CN102462685B (zh) * | 2010-11-10 | 2014-07-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种咪达唑仑组合物、其制备方法及用途 |
CN107260672A (zh) | 2011-05-13 | 2017-10-20 | 欧洲凯尔特公司 | 包含纳洛酮的鼻内药物剂型 |
TW201414751A (zh) | 2012-07-09 | 2014-04-16 | 歐尼克斯治療公司 | 肽環氧酮蛋白酶抑制劑之前驅藥物 |
US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
US20200297734A1 (en) * | 2015-06-19 | 2020-09-24 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
US11045462B2 (en) * | 2016-06-14 | 2021-06-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods for treating neurological conditions and exposure to nerve agents |
WO2019226753A1 (en) | 2018-05-25 | 2019-11-28 | Ucb Biopharma Sprl | Benzodiazepine formulations |
WO2020129085A1 (en) | 2018-12-18 | 2020-06-25 | Cipla Limited | Intranasal formulation |
US20210322343A1 (en) * | 2020-04-15 | 2021-10-21 | Farzana Shaheen | Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders |
CN113209013B (zh) * | 2021-06-24 | 2023-04-07 | 新疆特丰药业股份有限公司 | 一种咪达唑仑液体制剂及其制备方法和用途 |
NL2031332B1 (en) | 2022-03-18 | 2023-09-29 | Plethora Therapeutics B V | Transmucosal delivery of psychoactive compounds |
NL2031331B1 (en) | 2022-03-18 | 2023-09-29 | Plethora Therapeutics B V | Transmucosal delivery of a short-acting psychedelic compound |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3812853A (en) | 1971-11-17 | 1974-05-28 | P Crain | Apparatus for applying medication or the like to human nasal passages |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US5132114A (en) | 1985-05-01 | 1992-07-21 | University Of Utah Research Foundation | Compositions and methods of manufacture of compressed powder medicaments |
US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
ATE60226T1 (de) | 1986-03-10 | 1991-02-15 | Kurt Burghart | Pharmazeutikum sowie verfahren zu seiner herstellung. |
US4673679A (en) | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
US4782047A (en) | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
DE3734306A1 (de) | 1987-10-10 | 1989-04-27 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung fuer fliessfaehige medien |
US4973596A (en) | 1988-05-20 | 1990-11-27 | Barr Laboratories, Inc. | Method of administering a narcotic analgesic and dosage forms therefor |
US4950664A (en) * | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5397771A (en) * | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
WO1991016929A1 (en) * | 1990-05-10 | 1991-11-14 | Novo Nordisk A/S | A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols |
FR2662672B1 (fr) | 1990-05-31 | 1992-08-21 | Aerosols & Bouchage | Dispensateur de melange. |
US5166202A (en) * | 1990-09-19 | 1992-11-24 | Trustees Of The University Of Pennsylvania | Method for the treatment of panic disorder |
PT656207E (pt) | 1991-06-10 | 2001-11-30 | Schering Corp | Formulacoes de aerossois sem clorofluorocarbonetos |
GB9125699D0 (en) | 1991-12-03 | 1992-01-29 | Glaxo Group Ltd | Device |
GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
ES2127837T3 (es) | 1992-10-19 | 1999-05-01 | Dura Pharma Inc | Inhalador para polvo seco. |
US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
GB9409778D0 (en) | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
CA2152684A1 (en) | 1994-07-01 | 1996-01-02 | Richard Anthony Henry | Aerosol delivery of midazolam |
US5529787A (en) | 1994-07-07 | 1996-06-25 | Alza Corporation | Hydromorphone therapy |
CA2201358C (en) | 1994-09-30 | 2004-06-08 | Jurgen Regenold | Pharmaceutical composition |
US5866143A (en) | 1995-03-24 | 1999-02-02 | El Khoury And Stein, Ltd. | Topical application of opioid drugs such as morphine for relief of itching and skin disease |
US5622166A (en) | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
US5637314A (en) | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
US5948389A (en) | 1995-06-07 | 1999-09-07 | El Khoury & Stein, Ltd. | Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics |
US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
WO1998002186A1 (en) | 1996-07-11 | 1998-01-22 | Farmarc Nederland B.V. | Inclusion complex containing indole selective serotonin agonist |
DE19709702A1 (de) | 1997-03-10 | 1998-09-17 | Wolff Walsrode Ag | Lackbindemittelzubereitungen, deren Herstellung und Verwendung |
US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
FR2772271B1 (fr) | 1997-12-11 | 2000-09-01 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
JP2003522207A (ja) * | 1998-02-23 | 2003-07-22 | サイクロプス・イーエイチエフ | 高エネルギーシクロデキストリン複合体 |
US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
DE19807921A1 (de) | 1998-02-25 | 1999-08-26 | Pfeiffer Erich Gmbh & Co Kg | Austrag-Steuerung für einen Medien-Spender |
US6608073B1 (en) | 1998-10-14 | 2003-08-19 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
WO2000074651A1 (de) | 1999-06-02 | 2000-12-14 | Hexal Ag | Pharmazeutische zusammensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslichen wirkstoffen |
ES2304969T3 (es) | 1999-07-26 | 2008-11-01 | Sk Holdings Co., Ltd. | Composiciones anticonvulsivas transnasales. |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
AU7937500A (en) | 1999-10-27 | 2001-05-08 | Farmarc Nederland Bv | Pharmaceutical composition containing midazolam |
US6610271B2 (en) | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
US20040176359A1 (en) | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
WO2002089849A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
ATE415155T1 (de) | 2001-05-24 | 2008-12-15 | Alexza Pharmaceuticals Inc | Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation |
GB0116107D0 (en) | 2001-06-30 | 2001-08-22 | West Pharm Serv Drug Res Ltd | Pharmaceutical composition |
GB0130964D0 (en) | 2001-12-24 | 2002-02-13 | Special Products Ltd | Pharmaceutical composition |
US20060039869A1 (en) | 2004-08-17 | 2006-02-23 | Daniel Wermeling | Intranasal delivery of antipsychotic drugs |
-
2004
- 2004-01-14 GB GBGB0400804.1A patent/GB0400804D0/en not_active Ceased
-
2005
- 2005-01-13 CN CN2005800078503A patent/CN1929816B/zh active Active
- 2005-01-13 BR BRPI0506868-1A patent/BRPI0506868A/pt not_active Application Discontinuation
- 2005-01-13 NZ NZ548454A patent/NZ548454A/en unknown
- 2005-01-13 JP JP2006548318A patent/JP5085138B2/ja active Active
- 2005-01-13 US US11/034,474 patent/US7700588B2/en active Active
- 2005-01-13 PT PT05701515T patent/PT1703896E/pt unknown
- 2005-01-13 PL PL05701515T patent/PL1703896T3/pl unknown
- 2005-01-13 WO PCT/EP2005/050133 patent/WO2005067893A2/en active Application Filing
- 2005-01-13 CA CA2553890A patent/CA2553890C/en active Active
- 2005-01-13 MX MXPA06008086A patent/MXPA06008086A/es unknown
- 2005-01-13 DE DE602005011753T patent/DE602005011753D1/de active Active
- 2005-01-13 EA EA200601309A patent/EA014096B1/ru not_active IP Right Cessation
- 2005-01-13 KR KR1020067016194A patent/KR20060130175A/ko not_active Application Discontinuation
- 2005-01-13 AT AT05701515T patent/ATE417600T1/de active
- 2005-01-13 AU AU2005205072A patent/AU2005205072B2/en active Active
- 2005-01-13 DK DK05701515T patent/DK1703896T3/da active
- 2005-01-13 ES ES05701515T patent/ES2319667T3/es active Active
- 2005-01-13 EP EP05701515A patent/EP1703896B1/en active Active
- 2005-09-08 US US11/221,663 patent/US20060009447A1/en not_active Abandoned
-
2006
- 2006-07-10 IL IL176774A patent/IL176774A0/en unknown
- 2006-07-26 NO NO20063453A patent/NO336916B1/no active Protection Beyond IP Right Term
- 2006-07-31 ZA ZA200606310A patent/ZA200606310B/xx unknown
-
2023
- 2023-03-16 NO NO2023011C patent/NO2023011I1/no unknown
- 2023-03-21 NO NO2023014C patent/NO2023014I1/no unknown
- 2023-07-11 FI FIC20230023C patent/FIC20230023I1/fi unknown
- 2023-07-19 FI FIC20230024C patent/FIC20230024I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FIC20230024I1 (fi) | Farmaseuttisia koostumuksia, jotka käsittävät midatsolaamia suuressa pitoisuudessa | |
UA97795C2 (uk) | Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки | |
WO2010022055A3 (en) | 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders | |
LU92232I9 (xx) | ||
WO2007077561A3 (en) | Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents | |
YU44404A (sh) | Postupak za identifikovanje ciljnih enzima tumora | |
AR059948A1 (es) | Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa | |
TNSN07322A1 (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
TW200716204A (en) | Pharmaceutical composition | |
WO2010054167A3 (en) | Limited proteolysis of cd2ap and progression of renal disease | |
CY1116831T1 (el) | ΧΡΗΣΗ 24-norUDCA | |
CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
IN2012DN00359A (xx) | ||
WO2008128191A3 (en) | Oral cephalotaxine dosage forms | |
HK1120417A1 (en) | Stable nanoparticle formulations | |
MY160005A (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt | |
MX2012000680A (es) | Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-1 9,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2 ,4,9,14,16,18(26),20,22-nonaeno. | |
DE50312224D1 (de) | Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel | |
WO2007146375A3 (en) | Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer | |
EA200901145A1 (ru) | Применение рибофлавина в лечении гипертензии | |
MXPA05007253A (es) | Sales novedosas de derivados anticonvulsivantes. | |
WO2006121857A3 (en) | Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses | |
MX2010007607A (es) | (e)-n-{3-[1-(8-fluoro-11h-10-oxa-1-aza-dibenzo [a,d] ciclohepten-5iliden)-propil}-fenil}-metilsulfon amida como modulador de receptor glucocorticoide para el tratamiento de reumatoide. | |
WO2008045686A3 (en) | Enantiomerically enriched iminopyrrolidone azirdine compositions | |
UA44173U (ru) | Фармацевтическая композиция в форме суппозиториев для лечения проктологических заболеваний |